Cargando…

E-cadherin as a prognostic indicator in primary breast cancer

Epithelial cadherin (E-CD) is a member of the cadherin family of cell adhesion molecules and has been implicated as an invasion suppressor molecule in vitro and in vivo. We analysed 174 breast tumours from the Nottingham/Tenovus Breast Cancer Series immunohistochemically for E-CD expression using th...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, C, Rampaul, R S, Pinder, S E, Bell, J A, Wencyk, P M, Blamey, R W, Nicholson, R I, Robertson, J F R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364028/
https://www.ncbi.nlm.nih.gov/pubmed/11747340
http://dx.doi.org/10.1054/bjoc.2001.2178
_version_ 1782153851979169792
author Parker, C
Rampaul, R S
Pinder, S E
Bell, J A
Wencyk, P M
Blamey, R W
Nicholson, R I
Robertson, J F R
author_facet Parker, C
Rampaul, R S
Pinder, S E
Bell, J A
Wencyk, P M
Blamey, R W
Nicholson, R I
Robertson, J F R
author_sort Parker, C
collection PubMed
description Epithelial cadherin (E-CD) is a member of the cadherin family of cell adhesion molecules and has been implicated as an invasion suppressor molecule in vitro and in vivo. We analysed 174 breast tumours from the Nottingham/Tenovus Breast Cancer Series immunohistochemically for E-CD expression using the mouse monoclonal antibody HECD-1 (Zymed Laboratories Inc.). In normal epithelial cells E-CD was strongly expressed at cell–cell boundaries. 66% of the breast cancers examined had reduced intensity of E-CD expression with 74% having significant reductions in the proportion of E-CD-positive tumour cells. Using a combined intensity/proportion score, significant associations were found between E-CD expression and tumour type (P ≤ 0.001). ER status (P = 0.026) and histological grade (P = 0.031). Expression of E-CD was not found to be related to recurrence, distant metastases, lymph node stage, vascular invasion, primary tumour size, prognostic group or survival. Thus E-CD expression in human breast cancer appears to have minimal prognostic value, but may have a role as a phenotypic marker. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2364028
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23640282009-09-10 E-cadherin as a prognostic indicator in primary breast cancer Parker, C Rampaul, R S Pinder, S E Bell, J A Wencyk, P M Blamey, R W Nicholson, R I Robertson, J F R Br J Cancer Regular Article Epithelial cadherin (E-CD) is a member of the cadherin family of cell adhesion molecules and has been implicated as an invasion suppressor molecule in vitro and in vivo. We analysed 174 breast tumours from the Nottingham/Tenovus Breast Cancer Series immunohistochemically for E-CD expression using the mouse monoclonal antibody HECD-1 (Zymed Laboratories Inc.). In normal epithelial cells E-CD was strongly expressed at cell–cell boundaries. 66% of the breast cancers examined had reduced intensity of E-CD expression with 74% having significant reductions in the proportion of E-CD-positive tumour cells. Using a combined intensity/proportion score, significant associations were found between E-CD expression and tumour type (P ≤ 0.001). ER status (P = 0.026) and histological grade (P = 0.031). Expression of E-CD was not found to be related to recurrence, distant metastases, lymph node stage, vascular invasion, primary tumour size, prognostic group or survival. Thus E-CD expression in human breast cancer appears to have minimal prognostic value, but may have a role as a phenotypic marker. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-12 /pmc/articles/PMC2364028/ /pubmed/11747340 http://dx.doi.org/10.1054/bjoc.2001.2178 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Parker, C
Rampaul, R S
Pinder, S E
Bell, J A
Wencyk, P M
Blamey, R W
Nicholson, R I
Robertson, J F R
E-cadherin as a prognostic indicator in primary breast cancer
title E-cadherin as a prognostic indicator in primary breast cancer
title_full E-cadherin as a prognostic indicator in primary breast cancer
title_fullStr E-cadherin as a prognostic indicator in primary breast cancer
title_full_unstemmed E-cadherin as a prognostic indicator in primary breast cancer
title_short E-cadherin as a prognostic indicator in primary breast cancer
title_sort e-cadherin as a prognostic indicator in primary breast cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364028/
https://www.ncbi.nlm.nih.gov/pubmed/11747340
http://dx.doi.org/10.1054/bjoc.2001.2178
work_keys_str_mv AT parkerc ecadherinasaprognosticindicatorinprimarybreastcancer
AT rampaulrs ecadherinasaprognosticindicatorinprimarybreastcancer
AT pinderse ecadherinasaprognosticindicatorinprimarybreastcancer
AT bellja ecadherinasaprognosticindicatorinprimarybreastcancer
AT wencykpm ecadherinasaprognosticindicatorinprimarybreastcancer
AT blameyrw ecadherinasaprognosticindicatorinprimarybreastcancer
AT nicholsonri ecadherinasaprognosticindicatorinprimarybreastcancer
AT robertsonjfr ecadherinasaprognosticindicatorinprimarybreastcancer